Integrity Financial’s AbCellera Biologics ABCL Stock Holding History

Integrity Financial’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.9K	Hold	10,000	–	–	0.02%	218
2025 Q4	$34.2K	Sell	10,000 -50	-0.5%	-$223	0.02%	215
2025 Q3	$50.6K	Hold	10,050	–	–	0.02%	199
2025 Q2	$34.5K	Sell	10,050 -2,000	-17%	-$4.98K	0.02%	211
2025 Q1	$26.9K	Hold	12,050	–	–	0.02%	203
2024 Q4	$35.3K	Hold	12,050	–	–	0.02%	181
2024 Q3	$31.3K	Hold	12,050	–	–	0.02%	172
2024 Q2	$35.7K	Hold	12,050	–	–	0.02%	167
2024 Q1	$54.6K	Hold	12,050	–	–	0.04%	150
2023 Q4	$68.8K	Sell	12,050 -1,000	-8%	-$4.63K	0.05%	136
2023 Q3	$60K	Buy	+13,050	New	+$79.4K	0.05%	137

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Integrity Financial's ABCL Position: Q1 2026 in Review

Integrity Financial held its AbCellera Biologics (ABCL) position steady in Q1 2026 at 10,000 shares worth $34.9K. The position accounts for 0.02% of the portfolio, ranked #218.

Integrity Financial first reported a position in ABCL in Q3 2023 and has held it in 11 quarters since. The position peaked at $68.8K in Q4 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Integrity Financial held 10,000 shares of AbCellera Biologics worth $34.9K as of Q1 2026.
Integrity Financial left its AbCellera Biologics share count unchanged in Q1 2026.
AbCellera Biologics made up 0.02% of Integrity Financial's portfolio in Q1 2026, its #218 holding.
Integrity Financial first reported a position in AbCellera Biologics in Q3 2023 and has held it in 11 quarters since.
Integrity Financial's AbCellera Biologics position peaked at $68.8K in Q4 2023.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Integrity Financial's 13F filing for Q1 2026, filed 14 May 2026.